# Vyra Peptides — Metabolic & Weight Research Peptides > Vyra Peptides is a reference desk for Metabolic & Weight Research peptides — tesamorelin and retatrutide — summarized from peer-reviewed literature through the visceral adipose research angle. A digest, not a vendor or clinic. A data-forward reading desk for the published science on tesamorelin and retatrutide — what each was actually studied for, in which populations, and how the effect sizes hold up under scrutiny. ## The short version Vyra Peptides is a reading desk, not a store. It collects what the published research literature actually says about two peptides that sit at the forefront of metabolic science: tesamorelin and retatrutide. A *peptide* is a short chain of amino acids — far smaller than a full protein — engineered to interact with specific cellular receptors involved in metabolism, appetite, and fat distribution. This desk does one job: it reports, in plain language and with citations, what each compound was tested in, what the numbers showed, and what the evidence does not yet cover. Tesamorelin is FDA-approved for a specific HIV-related condition; all other uses are off-label and investigational. Retatrutide is still in late-stage clinical trials and has no approved indication anywhere. We do not sell anything, we do not give medical advice, and we never list a human dose. ## What are research peptides? Proteins in the body — a hormone, a receptor-binding signal, an enzyme — are long chains of amino acids folded into functional shapes. A *peptide* is a far shorter chain of the same amino acids, sometimes only a few links long. Because they are compact and specific, peptides can act like keys that fit particular locks (receptors) on cell surfaces, switching metabolic processes on or off without touching everything else at once. A *research peptide* in the metabolic space is one that has been synthesized and studied in clinical trials or preclinical work — but may not yet hold broad regulatory approval. Sellers of research-grade material describe these compounds as for laboratory research only. That framing matters: even when a peptide has some approved use (as tesamorelin does), dosing, long-term safety outside the approved indication, and real-world effectiveness in general populations remain largely unestablished. When this site reports a number — a percentage reduction in visceral fat, an HbA1c delta — it reports it exactly as the study reported it: population, duration, dose used in that trial. ## How these two fit into metabolic research The two peptides on this desk approach metabolic fat from different mechanistic angles, which is exactly why they sit together. - [**Tesamorelin**](/tesamorelin) is the lead. It is a 44-amino-acid synthetic analogue of human growth hormone-releasing hormone (GHRH), approved by the FDA in 2010 to reduce excess visceral fat in HIV patients with antiretroviral-related lipodystrophy. It works by amplifying the body's own pulsatile GH rhythm rather than supplying exogenous GH, and a 2026 meta-analysis of five RCTs confirms visceral adipose tissue reduction of ~27.7 cm2 alongside significant reductions in hepatic fat [1]. - [**Retatrutide**](/retatrutide) is the investigational counterpart. It is a single molecule that activates three receptors simultaneously — GLP-1, GIP, and glucagon — combining appetite suppression, improved glucose-dependent insulin secretion, and added energy expenditure through the glucagon arm. Phase 2 data at the highest dose showed ~24% body-weight reduction at 48 weeks [11]. Together they represent two very different research strategies for metabolic fat: one that works from within the growth-hormone axis to target visceral depots selectively, and one that coordinates three incretin/glucagon signals to drive total body-weight reduction. Use the directory to read each compound in depth, or [compare these peptides](/compare) side by side. ## A note on how this desk reads the evidence Vyra Peptides is a data-forward literature digest. Each compound page summarizes the published studies, cites them by number, and links to a single shared [references list](/references). Numbers are quoted as the study reported them — effect sizes, confidence intervals, p-values, population sizes. Where the study population limits generalizability (for example, trials conducted exclusively in HIV-positive adults on antiretroviral therapy), the page says so plainly. Regulatory status, WADA classification, and the distinction between an approved indication and off-label investigational use are treated as part of the scientific record, not footnotes. The aim is a precise, accurate map of what has been measured and what remains open — so that the distance between current evidence and broader claims is visible. --- A data-forward literature digest — effect sizes and citations, not recommendations, and nothing for sale.